153 related articles for article (PubMed ID: 27226420)
1. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
Srinivas NR
Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Einolf HJ; Lin W; Won CS; Wang L; Gu H; Chun DY; He H; Mangold JB
Drug Metab Dispos; 2017 Dec; 45(12):1304-1316. PubMed ID: 28912253
[TBL] [Abstract][Full Text] [Related]
3. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
Hamberg P; Woo MM; Chen LC; Verweij J; Porro MG; Zhao L; Li W; van der Biessen D; Sharma S; Hengelage T; de Jonge M
Cancer Chemother Pharmacol; 2011 Sep; 68(3):805-13. PubMed ID: 21706316
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat: first global approval.
Garnock-Jones KP
Drugs; 2015 Apr; 75(6):695-704. PubMed ID: 25837990
[TBL] [Abstract][Full Text] [Related]
6. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.
Van Veggel M; Westerman E; Hamberg P
Clin Pharmacokinet; 2018 Jan; 57(1):21-29. PubMed ID: 28667459
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M; Woo MM; Schran H; Mu S; Nedelman J; Capdeville R
Eur J Clin Pharmacol; 2015 Jun; 71(6):663-672. PubMed ID: 25939707
[TBL] [Abstract][Full Text] [Related]
9. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Suresh PS; Devaraj VC; Srinivas NR; Mullangi R
Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27511598
[TBL] [Abstract][Full Text] [Related]
10. The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro GI; Frank R; Dandamudi UB; Hengelage T; Zhao L; Gazi L; Porro MG; Woo MM; Lewis LD
Cancer Chemother Pharmacol; 2012 Feb; 69(2):555-62. PubMed ID: 22057852
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
15. Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression.
Moreno-Yruela C; Fass DM; Cheng C; Herz J; Olsen CA; Haggarty SJ
ACS Chem Neurosci; 2019 Aug; 10(8):3769-3777. PubMed ID: 31330099
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and histone deacetylase inhibitors.
Goey AK; Sissung TM; Peer CJ; Figg WD
Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
[TBL] [Abstract][Full Text] [Related]
18. Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).
Fredenhagen A; Kittelmann M; Oberer L; Kuhn A; Kühnöl J; Délémonté T; Aichholz R; Wang P; Atadja P; Shultz MD
Drug Metab Dispos; 2012 May; 40(5):1041-50. PubMed ID: 22344701
[TBL] [Abstract][Full Text] [Related]
19. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.
Moj D; Britz H; Burhenne J; Stewart CF; Egerer G; Haefeli WE; Lehr T
Cancer Chemother Pharmacol; 2017 Nov; 80(5):1013-1026. PubMed ID: 28988277
[TBL] [Abstract][Full Text] [Related]
20. Progress of HDAC inhibitor panobinostat in the treatment of cancer.
Li X; Zhang J; Xie Y; Jiang Y; Yingjie Z; Xu W
Curr Drug Targets; 2014 Jun; 15(6):622-34. PubMed ID: 24597570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
